Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anupama Gorde"'
Autor:
Suresh B. Patankar, Anupama Gorde, Kalpana Joshi, Kishor Suryawanshi, Pravin Soni, Tejas Shah, Sagar Patankar, Diwakar Jha, Rajesh Raje, Hrishikesh Rangnekar
Publikováno v:
Journal of Ayurveda and Integrative Medicine, Vol 13, Iss 4, Pp 100653- (2022)
Background: Novel corona virus disease-2019 (COVID-19) pandemic is a significant contributor to morbidity and mortality in affected individuals. Modulating the immune response in COVID-19 is now an established treatment approach. Polyherbal formulati
Externí odkaz:
https://doaj.org/article/a0e06068f2484d3898ac2e37e8c96c6e
Autor:
Suresh B. Patankar, Anupama Gorde, Sagar Patankar, Rajesh Raje, Chadrashekhar Gillurkar, Pranjal Ausekar, Gaurav Patil
Traditional medicine has demonstrated its efficacy in treating a vast array of ailments, including infectious ones, over the years. Because of their immunomodulatory and other pharmacological actions, polyherbal formulations are suitable for COVID-19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f95aa3c9c7234be7427873b89f5a470
Autor:
Suresh B. Patankar, Anupama Gorde, Kalpana Joshi, Kishor Suryawanshi, Pravin Soni, Tejas Shah, Sagar Patankar, Diwakar Jha, Rajesh Raje, Hrishikesh Rangnekar
Publikováno v:
Journal of Ayurveda and integrative medicine. 13(4)
Novel corona virus disease-2019 (COVID-19) pandemic is a significant contributor to morbidity and mortality in affected individuals. Modulating the immune response in COVID-19 is now an established treatment approach. Polyherbal formulations have lon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d228918ab124d69e751703f2b6947f22
https://pubmed.ncbi.nlm.nih.gov/36311474
https://pubmed.ncbi.nlm.nih.gov/36311474
Autor:
Suresh Balkrishna Patankar, Sagar Patankar, Anupama Gorde, Pravin Soni, Hrishikesh Rangnekar, Kishor Suryawanshi, Diwakar Jha, Rajesh Raje, Tejas Shah, Kalpana Joshi
ObjectiveTo assess the efficacy and safety of polyherbal formulation (designated as IP) in comparison to placebo as add on to the standard of care (SoC) among patients with mild to moderate novel corona virus disease 2019 (COVID-19)MethodsLaboratory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::114a3ec709bbd83e87cef5299e0e51c6
https://doi.org/10.1101/2021.05.14.21256900
https://doi.org/10.1101/2021.05.14.21256900